Galderma Cuts Topical Derma R&D In Favor Of Systemic Treatments
Executive Summary
Significant shifts in innovation for atopic dermatitis are behind the decision to close down the current R&D center of Nestlé group prescription dermatology business Galderma. The move affects around 550 employees in Sophia Antipolis, France, with only a small proportion likely to be offered jobs in a planned new center of excellence.
You may also be interested in...
Finance Watch: Signs Of Life? A Small Offering, Three New Filings And Galderma Hints At An IPO
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.
Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024
Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.
JAK Inhibitors Have Dupixent In Their Sights For Atopic Dermatitis
Analysts predict that Sanofi and Regeneron's Dupixent is going to dominate the severe eczema market but the oral options of Lilly/Incyte's baricitinib and AbbVie's upadacitinib are progressing through the pipeline to make a challenge.